NYSEAMERICAN:CVRS Corindus Vascular Robotics (CVRS) Stock Price, News & Analysis $4.27 0.00 (0.00%) As of 11/27/2019 Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Corindus Vascular Robotics Stock (NYSEAMERICAN:CVRS) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get CVRS alerts:Sign Up Key Stats Today's Range$4.27▼$4.2750-Day Range$4.27▼$4.2752-Week Range$0.78▼$4.40VolumeN/AAverage Volume1.99 million shsMarket Capitalization$891.08 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Corindus Vascular Robotics, Inc. designs, manufactures, and sells robotic-assisted systems for use in interventional vascular procedures in the United States and internationally. The company offers CorPath system, a medical device with robotic-assisted precision for coronary and peripheral interventional procedures. Its CorPath system allows the physician to perform procedures with a control console located within an interventional cockpit; and CorPath GRX system enables the precise robotic-assisted control of guide catheters, guidewires, and balloon/stent devices from the safety of a radiation-shielded interventional cockpit. The company sells its products through direct sales force, as well as through distributor and partnership relationships. It serves vascular, coronary, peripheral vascular, neurointerventional, and structural heart markets. Corindus Vascular Robotics, Inc. is headquartered in Waltham, Massachusetts. Read More Receive CVRS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Corindus Vascular Robotics and its competitors with MarketBeat's FREE daily newsletter. Email Address CVRS Stock News HeadlinesCorindus Vascular Robotics, Inc.March 22, 2024 | thestreet.comHealthCor Partners Fund II, L.P.'s Net WorthFebruary 9, 2024 | benzinga.comThe Coin That Could Define Trump’s Crypto PresidencyWhen Trump returned to office, one of his first moves was to tap PayPal’s former COO, David Sacks, as a top advisor on crypto and AI. That alone signaled a shift. But insiders close to D.C. aren’t just talking crypto policy—they’re quietly buying something most retail investors have missed. While the crowd chases Bitcoin to $150,000, Weiss Ratings expert Juan Villaverde believes a different coin—already backed by giants like Google, Visa, and PayPal—could soon become crypto’s “Third Giant.”August 10 at 2:00 AM | Weiss Ratings (Ad)Robotics, AI And Cognitive Computing Are Changing Organizations Even Faster Than We ThoughtMay 28, 2023 | forbes.com2023-2030 Robotic Vascular Catheter System Market Size with [94 Pages] includes Growth Rate Analysis | New Report by Absolute ReportsApril 21, 2023 | marketwatch.comRobotics & AIMarch 2, 2023 | techcrunch.comTGanymed Robotics Raises Additional €15 M through Series B Extension Bringing Total Amount to €36 MJanuary 29, 2023 | finance.yahoo.comThe Worldwide Industrial Robotics Industry is Expected to Reach $43.9 Billion in 2027January 17, 2023 | finance.yahoo.comSee More Headlines CVRS Stock Analysis - Frequently Asked Questions How have CVRS shares performed this year? Corindus Vascular Robotics' stock was trading at $4.27 at the beginning of 2025. Since then, CVRS shares have increased by 0.0% and is now trading at $4.27. How were Corindus Vascular Robotics' earnings last quarter? Corindus Vascular Robotics Inc (NYSEAMERICAN:CVRS) announced its earnings results on Tuesday, August, 7th. The medical equipment provider reported ($0.06) earnings per share for the quarter, missing analysts' consensus estimates of ($0.05) by $0.01. The medical equipment provider had revenue of $1.67 million for the quarter, compared to the consensus estimate of $3 million. How do I buy shares of Corindus Vascular Robotics? Shares of CVRS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Corindus Vascular Robotics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Corindus Vascular Robotics investors own include Amarin (AMRN), TransEnterix (TRXDW), Micron Technology (MU), Advanced Micro Devices (AMD), NVIDIA (NVDA), Helios and Matheson Analytics (HMNY) and Meta Platforms (META). Company Calendar Last Earnings8/07/2018Today8/10/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSEAMERICAN SectorMedical Industry Medical Appliances & Equipment Sub-IndustryMedical Equipment Current SymbolNYSEAMERICAN:CVRS Previous SymbolNYSEMKT:CVRS CIKN/A Webwww.corindus.com Phone+1-508-6533335FaxN/AEmployees90Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares208,685,000Free FloatN/AMarket Cap$891.08 million OptionableNot Optionable BetaN/A A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for August 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free Report This page (NYSEAMERICAN:CVRS) was last updated on 8/10/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | Sponsored"Death Spiral" Threatening Your SavingsThe "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…Goldco Precious Metals | SponsoredProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredNational 'Stock Market Reset' Coming September 30 (New WH Order)Crash Coming Sept 30? Analysts Warn of New Crisis A new problem on the U.S. power grid is putting millions ...Altimetry | SponsoredGreen Light for These StocksGuess Who Washington Will Partner With Next? The U.S. government just made a bold $400 million move... beco...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Corindus Vascular Robotics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Corindus Vascular Robotics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.